We describe 2 highly treatment-experienced patients with unusual tipranavir susceptibility profiles. Patient 1 had a 5-year history of protease inhibitor exposure, and his genotype revealed multiple protease mutations interpreted as possible resistance to darunavir and tipranavir. Phenotypic testing, however, demonstrated susceptibility to darunavir and hypersusceptibility to tipranavir. Initiation of a new regimen of tenofovir/emtricitabine, efavirenz, tipranavir/ritonavir, and raltegravir provided a sustained immunologic and virologic response.
Patient 2 also had extensive prior protease inhibitor exposure and evolved high-level resistance to darunavir but maintaining full phenotypic sensitivity to tipranavir. Initiation of a new regimen (tipranavir/ritonavir and raltegravir, recycled zidovudine, lamivudine, tenofovir, and maraviroc) provided a fully suppressive virologic response.
The genotypic profiles of both patients included mutations that predict hypersusceptibility and improved response to tipranavir (24I, 50L/V, 54L, and 76V). In addition to using novel agents from new classes, clinicians should use updated resistance information for existing classes to create effective salvage regimens.
From the *Cooper University Hospital, UMDNJ-Robert Wood Johnson Medical School, Camden, NJ; †Georgetown University Medical Center, Washington, DC; and ‡Lightsource Medical Group, Los Angeles, CA.
Correspondence to: John D. Baxter, MD, Division of Infectious Diseases, Cooper University Hospital, UMDNJ-Robert Wood Johnson Medical School, Suite 513, 3 Cooper Plaza, Camden, NJ 08103. E-mail: firstname.lastname@example.org.
The authors have no conflicts of interest to disclose.
This article was supported by Boehringer Ingelheim Pharmaceuticals, Inc.
The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors and were involved at all stages of article development.